Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.72 |
| ▸ | AKT1 | P31749 | 12/20 | 0.42 |
| ▸ | AKT2 | P31751 | 12/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071100 | 0.85 | F2RL1 (0.77) | F2RL1AKT1AKT2GBA1 | |
| SCHEMBL31499 | 0.84 | F2RL1 (0.62) | F2RL1AKT1AKT2PKLRFASN | |
| SCHEMBL31519 | 0.83 | F2RL1 (1.00) | F2RL1FASNSLC2A1 | |
| SCHEMBL15071143 | 0.83 | F2RL1 (0.74) | F2RL1AKT1AKT2GBA1SLC2A1 | |
| SCHEMBL15071155 | 0.82 | F2RL1 (0.73) | F2RL1AKT1AKT2FASN | |
| SCHEMBL15071158 | 0.82 | F2RL1 (0.73) | F2RL1 | |
| SCHEMBL15071152 | 0.81 | F2RL1 (0.75) | F2RL1FASNGBA1SLC2A1 | |
| SCHEMBL15071151 | 0.81 | F2RL1 (0.75) | F2RL1AKT1AKT2FASNGBA1 | |
| SCHEMBL31491 | 0.81 | F2RL1 (0.75) | F2RL1AKT1AKT2FASNSLC2A1 | |
| SCHEMBL31526 | 0.80 | F2RL1 (0.90) | F2RL1FASNSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885AKT1 669/4885AKT2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.